These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1090 related items for PubMed ID: 26640956

  • 21. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.
    Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG.
    HIV Clin Trials; 2013; 14(6):274-83. PubMed ID: 24334180
    [Abstract] [Full Text] [Related]

  • 22. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L.
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [Abstract] [Full Text] [Related]

  • 23. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
    Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrão R, Sola R, Bertasso A, Passe And S, Stancic S.
    HIV Clin Trials; 2012 Mar; 13(3):142-52. PubMed ID: 22592094
    [Abstract] [Full Text] [Related]

  • 24. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [Abstract] [Full Text] [Related]

  • 25. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV, VITAL-1 study team.
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [Abstract] [Full Text] [Related]

  • 26. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators.
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
    El-Karaksy HM, Mogahed EA, El-Raziky MS, Saleh D, Besheer M, Mubarak S.
    J Interferon Cytokine Res; 2016 Jan; 36(1):1-8. PubMed ID: 26406390
    [Abstract] [Full Text] [Related]

  • 30. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM, ANRS HC27 BOCEPREVIH Study Group.
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [Abstract] [Full Text] [Related]

  • 31. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V.
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [Abstract] [Full Text] [Related]

  • 32. [Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients].
    Almeida PR, Tovo CV, Rigo JO, Zanin P, Alves AV, Mattos AA.
    Arq Gastroenterol; 2009 Jun; 46(2):132-7. PubMed ID: 19578615
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Liu B, Cai WP, Hu FY, Xu M, Lan Y, Tang XP.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [Abstract] [Full Text] [Related]

  • 38. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB.
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [Abstract] [Full Text] [Related]

  • 39. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Osinusi A, Bon D, Nelson A, Lee YJ, Poonia S, Shivakumar B, Cai SY, Wood B, Haagmans B, Lempicki R, Herrmann E, Sneller M, Polis M, Masur H, Kottilil S.
    J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
    [Abstract] [Full Text] [Related]

  • 40. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 55.